Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2024-12-12 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window in compliance with insider trading regulations. It references the upcoming declaration of unaudited financial results for the quarter ending December 31, 2024, but does not contain any financial data or results itself. The document is short (1255 characters) and serves as an announcement related to trading restrictions rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-12-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization procedures for securities for the period 01.11.2024 to 30.11.2024. It is addressed to stock exchanges and the company secretary, and it confirms regulatory compliance rather than providing financial data or reporting on company performance. The document length is short (3202 characters) and it is a certification letter rather than a financial report or announcement of a meeting or vote. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance certificate and does not contain financial statements or detailed report content.
2024-12-09 English
We are enclosing herewith the certificate dated December 3, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (DP) Regulations, 2018.
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization and related securities regulations for the period 01.11.2024 to 30.11.2024. It is addressed to stock exchanges and signed by the company secretary. The document is short (3202 characters) and primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory compliance filing related to securities and share dematerialization. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate filing rather than any other specific report type.
2024-12-09 English
Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated November 13, 2024, from AstraZeneca Pharma India Limited. It includes unaudited financial results for the quarter ended September 30, 2024, along with a limited review report from statutory auditors. The document contains a financial performance summary with revenue and profit figures for Q1, Q2, and H1 2024, and commentary from the CFO and Managing Director. It also includes key milestones, product launch updates, and changes in board members and senior management. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarterly and half-year results) indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report or a certification letter, but contains actual financial results and management commentary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2024
2024-12-05 English
Please find the enclosed intimation of the Company with respect to the captioned subject for your reference.
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges (BSE and NSE). It informs about a legal order received from the Income-tax Appellate Tribunal (ITAT) related to tax assessment years 2017-18 and 2018-19. The content includes details of the litigation, the opposing party, and expected financial implications. The document is a regulatory announcement about a legal proceeding rather than a full legal proceedings report or financial report. It is relatively short (3007 characters) and serves as a formal disclosure to the stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories like Legal Proceedings Report (LTR) or Audit Report (AR).
2024-12-04 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges about a recent order received from the Income-tax Appellate Tribunal (ITAT). It includes details of the litigation and expected financial implications but does not contain financial statements or detailed financial analysis. The document is a regulatory announcement about a legal proceeding rather than a full legal proceedings report or financial report. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.